EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Kostine, Marie; Finckh, Axel; Bingham, Clifton O; Visser, Karen; Leipe, Jan; Schulze-Koops, Hendrik; Choy, Ernest H; Benesova, Karolina; Radstake, Timothy R D J; Cope, Andrew P; Lambotte, Olivier; Gottenberg, Jacques-Eric; Allenbach, Yves; Visser, Marianne; Rusthoven, Cindy; Thomasen, Lone; Jamal, Shahin; Marabelle, Aurélien; Larkin, James; Haanen, John B A G; Calabrese, Leonard H; Mariette, Xavier; Schaeverbeke, Thierry

doi:10.1136/annrheumdis-2020-217139

Scientific article

English

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Published inAnnals of the Rheumatic Diseases, vol. 80, no. 1, p. 36-48

Publication date2021

Abstract

Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification and management.

Keywords

Arthritis
Autoimmunity
Inflammation
Multidisciplinary team care
Treatment

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Recherche clinique dans les rhumatismes inflammatoires (1010)

Citation (ISO format)

KOSTINE, Marie et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. In: Annals of the Rheumatic Diseases, 2021, vol. 80, n° 1, p. 36–48. doi: 10.1136/annrheumdis-2020-217139